Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

BACKGROUND: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-positive bacteria currently used for the treatment of complicated skin and skin structure infections and bacteremia, including right sided endocarditis. We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005. METHODS: A total of 4,640 strains from 23 medical centers located in 10 European countries, Turkey and Israel (SENTRY Program platform) were tested for susceptibility by reference broth microdilution methods according to Clinical and Laboratory Standards Institute guidelines and interpretative criteria. Mueller-Hinton broth was supplemented to 50 mg/L Ca(++ )for testing daptomycin. Results for oxacillin (methicillin)-resistant staphylococci and vancomycin-resistant enterococci were analyzed separately. RESULTS: Oxacillin resistance rates among Staphylococcus aureus varied from 2.1% in Sweden to 42.5% in the United Kingdom (UK) and 54.7% in Ireland (29.1% overall), while vancomycin resistance rates varied from 0.0% in France, Sweden and Switzerland to 66.7% in the UK and 71.4% in Ireland among Enterococcus faecium (17.9% overall). All S. aureus strains were inhibited at daptomycin MIC of 1 mg/L (MIC(50/90), 0.25/0.5 mg/L; 100.0% susceptible) and only one coagulase-negative staphylococci strain (0.1%) showed an elevated (>1 mg/L) daptomycin MIC value (4 mg/L). Among E. faecalis (MIC(50/90), 0.5/1 mg/L; 100% susceptible) the highest daptomycin MIC value was 2 mg/L; while among E. faecium (MIC(50/90), 2/4 mg/L; 100% susceptible) the highest MIC result was 4 mg/L. CONCLUSION: Daptomycin showed excellent in vitro activity against staphylococci and enterococci collected in European medical centers in 2005 and resistance to oxacillin, vancomycin or quinupristin/dalfopristin did not compromise its activity overall against these pathogens. Based on these results and those of previous publications, daptomycin appears to be an excellent therapeutic option for serious infections caused by oxacillin-resistant staphylococci and vancomycin-resistant enterococci in Europe

Avaliação do efeito da colostomia proximal na cicatrização de anastomoses colocólicas em ratos com obstrução intestinal

OBJETIVO: Avaliar o efeito da colostomia proximal na cicatrização de anastomoses colocólicas em ratos com obstrução intestinal. MÉTODO: 72 ratos foram divididos em três grupos: grupo controle (C), submetido à anastomose colocólica e à colostomia proximal na ausência de oclusão intestinal; grupo sem colostomia (SC), submetido à oclusão intestinal de 72 horas e à anastomose colocólica primária; grupo com colostomia (CC) submetido à oclusão intestinal de 72 horas, à anastomose colocólica primária e à colostomia proximal. A cicatrização anastomótica foi avaliada em dois períodos, nos 2º e 7º dias de pós-operatório, em relação à deiscência anastomótica, aderências, epitelização mucosa, pressão de ruptura e a variáveis histológicas por estudo convencional e informatizado. RESULTADOS: verificou-se maior tendência a deiscência anastomótica no grupo SC (12,5%), e elevada incidência de complicações da colostomia no grupo CC (13%), entretanto tais resultados não apresentaram diferença estatística significante. No que se refere às demais variáveis analisadas para verificação da cicatrização anastomótica deve-se considerar que houve equivalência entre os três grupos nos dois períodos analisados. CONCLUSÃO: Não há diferença entre a cicatrização de anastomoses colocólicas associadas ou não à colostomia proximal, em ratos com obstrução intestinal

Treatment of prosthetic vascular graft infections

International audienceProsthetic vascular graft infections require a medico-surgical treatment. A first-line, empirical, antimicrobial treatment could be administered in cases of severe sepsis, septic shock or mechanical complications such as aneurysm rupture or anastomotic leakage. A broad-spectrum combination (glycopeptide, beta-lactams, and aminoglycoside) is usually proposed. When bacteriological samples have identified the causal agent(s) and its antibiotics susceptibility, a treatment with a narrow spectrum will be prescribed during the 6 weeks following surgical treatment.When surgical treatment is suboptimal, a suppressive antibiotic therapy is administered lifelong. The surgical treatment for these patients is complex. It depends on the mechanism of infection, location of prosthetic graft, causal bacteria, and underlying diseases